These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29790415)

  • 1. A gene variant near ATM affects the response to metformin and metformin plasma levels: a post hoc analysis of an RCT.
    Out M; Becker ML; van Schaik RH; Lehert P; Stehouwer CD; Kooy A
    Pharmacogenomics; 2018 Jun; 19(8):715-726. PubMed ID: 29790415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
    Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
    Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients.
    Zaharenko L; Kalnina I; Geldnere K; Konrade I; Grinberga S; Židzik J; Javorský M; Lejnieks A; Nikitina-Zake L; Fridmanis D; Peculis R; Radovica-Spalvina I; Hartmane D; Pugovics O; Tkáč I; Klimčáková L; Pīrāgs V; Klovins J
    Eur J Endocrinol; 2016 Dec; 175(6):531-540. PubMed ID: 27609360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.
    Shikata E; Yamamoto R; Takane H; Shigemasa C; Ikeda T; Otsubo K; Ieiri I
    J Hum Genet; 2007; 52(2):117-122. PubMed ID: 17111267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).
    Joerger M; van Schaik RH; Becker ML; Hayoz S; Pollak M; Cathomas R; Winterhalder R; Gillessen S; Rothermundt C
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):167-72. PubMed ID: 25753371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients.
    Raj GM; Mathaiyan J; Wyawahare M; Priyadarshini R
    Drug Metab Pers Ther; 2018 Dec; 33(4):175-185. PubMed ID: 30433870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Protocol for the Study of Polymorphisms and Response to Metformin in Patients with Type 2 Diabetes in Trinidad.
    Clement Y; Singh S; Motilal S; Maharaj R; Nunez-Smith M
    Ethn Dis; 2020; 30(Suppl 1):211-216. PubMed ID: 32269463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of SLC22A1 rs622342 and ATM rs11212617 polymorphisms with metformin efficacy in patients with type 2 diabetes.
    Chen P; Cao Y; Guo Y; Xu Q; Wang X; Zhang L; Liu Z; Chen D; Chen S; Chen S
    Pharmacogenet Genomics; 2022 Feb; 32(2):67-71. PubMed ID: 34545025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai.
    Zhou Y; Ye W; Wang Y; Jiang Z; Meng X; Xiao Q; Zhao Q; Yan J
    Int J Clin Exp Pathol; 2015; 8(8):9533-42. PubMed ID: 26464716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts.
    van Leeuwen N; Nijpels G; Becker ML; Deshmukh H; Zhou K; Stricker BH; Uitterlinden AG; Hofman A; van 't Riet E; Palmer CN; Guigas B; Slagboom PE; Durrington P; Calle RA; Neil A; Hitman G; Livingstone SJ; Colhoun H; Holman RR; McCarthy MI; Dekker JM; 't Hart LM; Pearson ER
    Diabetologia; 2012 Jul; 55(7):1971-7. PubMed ID: 22453232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin.
    Kashi Z; Masoumi P; Mahrooz A; Hashemi-Soteh MB; Bahar A; Alizadeh A
    Diabetes Res Clin Pract; 2015 Apr; 108(1):78-83. PubMed ID: 25662675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer.
    Berstein LM; Iyevleva AG; Vasilyev D; Poroshina TE; Imyanitov EN
    Cell Cycle; 2013 Dec; 12(23):3681-8. PubMed ID: 24145224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes.
    Liang H; Xu W; Zhou L; Yang W; Weng J
    Diabet Med; 2017 Jul; 34(7):987-992. PubMed ID: 28321905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients.
    He R; Zhang D; Lu W; Zheng T; Wan L; Liu F; Jia W
    Diabetes Res Clin Pract; 2015 Jul; 109(1):57-63. PubMed ID: 26004431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
    Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
    J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms of organic cation transporters 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes mellitus: a systematic review protocol.
    Mato EPM; Guewo-Fokeng M; Faadiel Essop M; Owira PMO
    Syst Rev; 2018 Jul; 7(1):105. PubMed ID: 30041690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Pharmacogenet Genomics; 2010 Jan; 20(1):38-44. PubMed ID: 19898263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c.
    Christensen MM; Brasch-Andersen C; Green H; Nielsen F; Damkier P; Beck-Nielsen H; Brosen K
    Pharmacogenet Genomics; 2011 Dec; 21(12):837-50. PubMed ID: 21989078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin.
    Li Q; Liu F; Zheng TS; Tang JL; Lu HJ; Jia WP
    Acta Pharmacol Sin; 2010 Feb; 31(2):184-90. PubMed ID: 20139901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.
    Pérez-Gómez N; Fernández-Ortega MD; Elizari-Roncal M; Santos-Mazo E; la Maza-Pereg L; Calvo S; Alcaraz R; Sanz-Solas A; Vinuesa R; Saiz-Rodríguez M
    Pharmacogenomics; 2023 Aug; 24(12):651-663. PubMed ID: 37610884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.